prednisone has been researched along with bkt140 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhagat, G; Chen, J; Chiu, A; Choi, WW; Deng, L; Dybkaer, K; Farnen, JP; Ferreri, AJ; Hsi, ED; Huh, J; Manyam, GC; Martinez-Lopez, A; Montes-Moreno, S; Møller, MB; Orazi, A; Pham, L; Piris, MA; Ponzoni, M; Richards, KL; Shen, Q; Tzankov, A; van Krieken, JH; Visco, C; Winter, JN; Xu-Monette, ZY; Yin, L; Young, KH; Zhang, L; Zhao, X; Zu, Y | 1 |
1 other study(ies) available for prednisone and bkt140
| Article | Year |
|---|---|
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemokine CXCL12; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Germinal Center; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Oligopeptides; Prednisone; Prognosis; Receptors, CXCR4; Rituximab; Transcriptome; Tumor Suppressor Protein p53; Vincristine | 2015 |